cannabidiol enema (IcBD-01)
/ CannaMore Biotechs
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 12, 2026
Safety and Preliminary Clinical Outcomes of a Combined Cannabidiol and Sodium Propionate Enema in Refractory Ulcerative Proctitis: An Open-Label Pilot Study.
(PubMed, Inflamm Intest Dis)
- "In this open-label, proof-of-concept study, IcBD-01 was well tolerated and associated with clinically meaningful improvements. These hypothesis-generating findings warrant further evaluation in randomized, placebo-controlled trials."
Clinical data • Journal • Inflammatory Bowel Disease • Pain • Ulcerative proctitis
July 22, 2024
CannaMore Biotechs Announces Successful Completion of Phase 2a Clinical Trial for Cannabidiol-Based Treatment for Ulcerative Colitis
(PRNewswire)
- P2a | N=45 | NCT06353828 | Sponsor CannaMore Biotechs | "CannaMore Biotechs...is pleased to announce the successful completion of its Phase 2a clinical trial evaluating the safety and efficacy of a CBD-based patent protected formulation for patients with Ulcerative Colitis (UC)....Primary Endpoint Achieved: A significant number of patients demonstrated a reduction in Mayo scores, indicating a decrease in disease severity....Patient-Reported Outcomes (PRO): Most participants reported substantial improvements in their symptoms, including reduced abdominal pain and better overall well-being."
P2a data • Patient reported outcomes • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 2
Of
2
Go to page
1